<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43500">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01848925</url>
  </required_header>
  <id_info>
    <org_study_id>SGSC-003</org_study_id>
    <nct_id>NCT01848925</nct_id>
  </id_info>
  <brief_title>Study of SANGUINATE™ Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients</brief_title>
  <official_title>A Phase I Open-label, Randomized, Safety and Efficacy Study of SANGUINATE™ at Two Doses Levels Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prolong Pharmaceuticals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prolong Pharmaceuticals</source>
  <oversight_info>
    <authority>Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos</authority>
    <authority>Panama: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety of SANGUINATE™ versus Hydroxyurea in
      patients suffering from Sickle Cell Disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To Compare SANGUINATE™ and Hydroxyurea in Sickle Cell Disease patients.</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Compare pain management between SANGUINATE™ and Hydroxyurea using 0-10 Numeric Pain Scale.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>SANGUINATE™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG-bHb-CO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxyurea</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care for Sickle Cell treatment, 15 mg/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SANGUINATE™</intervention_name>
    <description>40 mg/mL intravenous infusion.</description>
    <arm_group_label>SANGUINATE™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxyurea</intervention_name>
    <description>Standard of care for Sickle Cell treatment, 15 mg/kg.</description>
    <arm_group_label>Hydroxyurea</arm_group_label>
    <other_name>Hydroxycarbamide</other_name>
    <other_name>Brand Names includes: Hydria, Droxia.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Homozygous (HbSS) Sickle Cell Anemia;

          -  Hb levels: &gt;6g/dL - &lt;10g/dL;

          -  Age : &gt;18 years old;

          -  Frequency of ER hospitalizations &lt; 6x/yr for SCD pain events   documented &quot;medical
             history&quot;.

        Exclusion Criteria:

          -  Patients, who are on chronic transfusion program, defined as regular transfusions
             every 2-8 weeks;

          -  Allergic to Hydroxyurea;

          -  History of clinical significant disease, as determined by the Investigator;

          -  History of allergy or major allergic reaction considered to be clinically significant
             by the Investigator;

          -  Screening assessments considered to be abnormal by the Investigator;

          -  Patient has sever pulmonary hypertension (index &gt;3 meters per sec);

          -  Donated blood within 60 days of screening or otherwise experienced blood loss of &gt;250
             mL within the same period;

          -  Intending to begin new concomitant drug therapy or over-the-counter medication
             anytime from scree4nin to the time of administration of study drug;
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenny M Galvez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Pablo Tobin Uribe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis F Uribe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion Reina Isabel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nestor Sosa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Punta Pacifica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angel Hernandez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion BIOS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hemant Misra, PhD</last_name>
    <email>hmisra@prolongpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fundacion BIOS</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel Hernandez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Angel Hernandez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundacion Reina Isabel</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis F Uribe, MD</last_name>
      <phone>57 (2) 680 6407</phone>
    </contact>
    <investigator>
      <last_name>Luis F Uribe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo TobinUribe</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenny M Galvez, MD</last_name>
      <phone>57 (4) 4459753</phone>
    </contact>
    <investigator>
      <last_name>Kenny M Galvez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PAMRI</name>
      <address>
        <city>Panama City</city>
        <country>Panama</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nestor Sosa, MD</last_name>
      <phone>507 265 5460</phone>
    </contact>
    <investigator>
      <last_name>Nestor Sosa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Panama</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 26, 2013</lastchanged_date>
  <firstreceived_date>April 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SANGUINATE</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
